Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 13, 2020
Daily News
October 13, 2020
- Big 4 Wholesalers Raided Again over Suspected Bid-Rigging
October 13, 2020
- Nippon Zoki Eyes Alzheimer’s as New R&D Focus, First Up Is Label Expansion for Pain Med
October 13, 2020
- Samsca IV Prodrug Shows Non-Inferiority to Oral Agent
October 13, 2020
- Nichi-Iko, Sanofi in Authorized Generic Pact for ComPlavin
October 13, 2020
- MHLW Revises Leaflets on HPV Vaccination, Issues Related Notification
October 13, 2020
- Keytruda Filed for Triple Negative Breast Cancer in Japan: MSD
October 13, 2020
- Kyorin Transfers IP Rights for Novel Immunomodulator to Irish Firm
October 13, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…